Krystal Biotech, Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from Q2 2023 to Q2 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Krystal Biotech, Inc. quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q2 2023 to Q2 2024.
- Krystal Biotech, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending June 30, 2024 was $16M.
- Krystal Biotech, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $12.9M.
- Krystal Biotech, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$140M, a 101% decline from 2021.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)